39 6.4 Re-MATCH Phase I Study .......................................................................... 40 7. OBJECTIVES/SPECIFIC AIMS/STUDY QUESTIONS ....................................40 7.1 Hypotheses ................................................................................................... 40 7.2 Study Obje ctives .......................................................................................... 40 8. STUDY DESIGN ......................................................................................................41 9. STUDY POPULATION ..........................................................................................46 10. INCL USION CRITERA .........................................................................................47 10.1 Inclusion Criteria ......................................................................................... 47 10.2 Exclusion Criteria ........................................................................................ 48 10.3 Inclusion of Women and Minorities ............................................................ 49 11. DESCRIPTION OF THE RECRUITMENT PROCESS .....................................49 11.1 Recruitment .................................................................................................. 49 11.2 Screening and Enrollment ............................................................................ 50 12. SAMPLE SIZE JUSTIFIC ATION ........................................................................51 13. DESCRIPTION OF INFORMED CONSENT PROCESS ..................................51 14. VOLUNTEER SCREENING PROCEDURES .....................................................51 15. STUDY PROCEDURES/STUDY INTERVENTIONS ........................................52 15.1 Overview ...................................................................................................... 52 15.2 Chemotherapy for Group A ......................................................................... 52 15.2.1 Induction Therapy ........................................................................................ 52 15.2.2 leukapheresis for peripheral blood mononuclear cells (pbmcs) .................. 53 15.2.3 PBSC Mobilization and Leukapheresis ....................................................... 53 15.2.4 Guidelines for Induction Therapy and PBSC collection.............................. 54 15.3 Consolidation ...............................................................................................